NTEC - Intec Pharma/MSD ink research deal; shares up 13%

Intec Pharma (NTEC) +13% premarket after announcing a new research collaboration agreement with MSD, the tradename of Merck & Co, USA.The details of the agreement are not disclosed."This new agreement builds upon the relationship we have enjoyed in prior research and allows the companies to leverage their combined experience in delivery," says Mr. Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma.Previously: Intec Pharma +14% on Merck collaboration (May 2019).

For further details see:

Intec Pharma/MSD ink research deal; shares up 13%